Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
Do you get DEXA scans routinely before starting ADT for prostate cancer or endocrine therapy for breast cancer?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Would you offer PMRT to a patient with pTisN1a left breast DCIS?
Do you offer hypofractionation or RNI for a pT1N0 high-grade primary neuroendocrine carcinoma of the breast?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
What is an acceptable upper limit for ipsilateral lung V8 Gy when using the FAST-Forward regimen with high tangents to cover limited axillary disease?
